Publikationen - Leibniz Universität Hannover

51. Ambulatory medication costs of patients with cystic fibrosis in Germany. Appl Health Econ
Health Policy 2009, accepted (with Eidt D, Wagner T, von der Schulenburg JM)
52. Persistenz und Frequenz von Verordnungen im Bereich der subkutanen allergen-spezifischen
Immuntherapie (SCIT) bei GKV-Patienten in Deutschland [Persistence and frequency of
prescriptions in subcutaneous allergen-specific immunotherapy in the statutory health
insurance]. Med Klin 2009; 104(7): 536–42 (with Claes C, von der Schulenburg JM)
53. Therapiehinweise im Lichte täglicher Praxis am Beispiel der Osteoporose. Gesundh ökon Qual
manag 2009, accepted (with Prenzler A, Zellner M, Kasch C et al)
54. Evaluation von Kosten der ambulanten Behandlung bei Mukoviszidose in Deutschland -
Übersicht über die Ergebnisse einer prospektiven Studie [Evaluation of costs for ambulatory
treatment of cystic fibrosis in Germany – Results from a prospective study]. Med Klin 2009,
104(7): 529-35 (with Eidt D, Wagner T, Reimann A et al)
55. Pharmakoökonomische Bewertung von Darunavir/r zur Therapie behandlungserfahrener HIV-
Patienten [Pharmocoeconomic evaluation of darunavir/r for treatment in experienced HIV
infected patients]. MMW Fortschr Med 2009; 151(II): 97–103 (with Stoll M, Claes C et al)
56. Krankheitskosten bei Endometriose [Cost of illness in endometriosis]. Geburtshilfe Frauenheilkd
2009, accepted (with Brandes I, Kleine-Budde K)
57. Quality of Life as an outcome in Alzheimer’s disease and other dementias– obstacles and goals.
BMC Neurology 2009, accepted (with Riepe MW, Förstl H, Frölich L et al)
58. Evaluation of Exenatide versus Insulin Glargine in Type 2 Diabetes: Cost-Effectiveness Analysis in
the German Setting. Diabetes Obes Metab 2009, accepted (with Smith-Palmer J, Timlin L,
Happich M, Goodall G)
59. Validity of the EQ-5D children version as a generic health outcome instrument in children and
adolescents with cystic fibrosis in Germany. BMC Paediatrics 2009, in review (with Eidt D,
Greiner W)
60. Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany.
Respiration 2009, in review (with Eidt D, von der Schulenburg JM, Reimann A)
61. A Structured Review of Studies on Health-Related Quality of life in Kidney Cancer, Hepatocellular
Carcinoma and Leukemia. Cancer Invest 2009, in review (with Liu J, von der
Schulenburg JM)
62. Cost-Effectiveness of Exemestane vs. Tamoxifen in Post-Menopausal Women with Early
Breast Cancer in Germany. Breast 2009, in review (with Braun S, Greiner W et al)
63. Kosteneffektivität von Quetiapin und Haloperidol bei Patienten mit partiell therapieresistenter
Schizophrenie. Gesundh ökon Qual manag 2009, in review (with Braun S, Zeidler J, von der
Schulenburg JM)
64. Cost of transfusion dependent myelodysplastic syndrome (MDS) from a German payers
perspective. Cancer Res 2009, in review (with Kühne F, Germing U, Lipp R et al.)